Kodiak Sciences Inc.
$33.87
-8.2%Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -7.8).
Valuation inputs: P/E -7.8, earnings yield N/A, momentum -8.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.5%, ROIC -73.7%).
Profitability stack: net margin 0.0%, ROE -1.5%, ROIC -73.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +55.2%, momentum -8.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Kodiak Sciences Inc. Market vs Earnings Trajectory
Performance Analysis
EPS Growth
Slight earnings decline may be temporary. Monitor future quarters for trend reversal.
Price-EPS Relationship
Price is rising despite declining earnings—caution advised as valuation may be stretched.
Stock Price Change
Over the 1Y period, stock price has increased by 753.1%.
P/E Ratio (TTM)
Relatively low P/E may indicate undervaluation or lower growth expectations.
Key Insight
Despite declining earnings (-9.7%), the stock price has risen (+753.1%). This disconnect suggests investors may be optimistic about future turnaround, but earnings recovery is critical to sustain the valuation.
Kodiak Sciences Inc. Fair Value Envelope
No Revenue Data
KOD has not reported any revenue values in the available annual periods.
Kodiak Sciences Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
KOD has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
KOD has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
KOD has not reported any net profit margin values in the available annual periods.
Kodiak Sciences Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Kodiak Sciences Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.
Kodiak Sciences Inc. Street Expectations Map
Wall Street analysts project that KOD stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 63.75, with estimates ranging from a low of 56.00 to a high of 80.00.
The consensus 1-year price target stands at 63.75, with estimates ranging from a low of 56.00 to a high of 80.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Kodiak Sciences Inc. Insider Positioning
During the last 12 months, insiders have purchased $58.22M and sold $499K worth of KOD shares, resulting in $57.73M of net buying activity.
3 Months
0
0.00
12.7K
496.76K
-497K
-$497K
3-6 Months
2.4M
55.00M
0
0.00
+55.0M
+$55.00M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
830.0K
3.23M
723
2.64K
+3.2M
+$3.22M
Top Buyers
Baker Bros. Advisors Lp
Director, 10 Percent Owner:
$55.15M
Perlroth Victor
Director, 10 Percent Owner, Officer: Chairman And Ceo
$1.34M
Borgeson John A.
Officer: See Remarks
$988K
Dahiyat Bassil I
Director
$149K
Levy Richard S
Director
$149K
Top Sellers
Borgeson John A.
Officer: Chief Financial Officer
$499K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $57.73M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
kod Dividend History
Learning Layer
Related Guides
Build conviction on KOD by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.